Dermata Therapeutics Inc. announced that the Australian Patent Office has accepted its patent application for a combination of Spongilla technology as a method for treating acne. The accepted application, titled "Compositions and methods for the treatment of skin conditions" (Australian Patent Application No. 2019419387), marks a key step in expanding the company's international intellectual property portfolio. The patent is expected to be officially issued in mid-January 2026, provided no opposition is filed within three months of publication. This development follows a similar patent issued in the United States, strengthening Dermata's position in advancing next-generation acne treatments.